Prevalence

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Prevalence

Post by Petr75 »

2020 Feb 8
King Fahd Medical City (KFMC), MOH, Riyadh, Saudi Arabia
Rising Prevalence of Multiple Sclerosis in Saudi Arabia, a Descriptive Study
https://pubmed.ncbi.nlm.nih.gov/3203547 ... ive-study/

Abstract

Background: In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS.

Method: In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region.

Results: As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia.

Conclusion: The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia.
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 Feb 12
Multiple Sclerosis Fellowship, Neurology Department, Boualicina Hospital, Mazandaran University of Medical Sciences, Iran
Does the Multiple Sclerosis (MS) Map Need to Change Again? An Update of MS Prevalence in Mazandaran Province of Iran in 2018
https://pubmed.ncbi.nlm.nih.gov/3205093 ... n-in-2018/

Abstract

Background: Information of Previous studies on the prevalence of MS, including our study conducted 12 years ago, used to shape global prevalence map of MS. According to those results, Iran placed in medium-prevalence MS region in the world Atlas of MS 2013.This study aimed to investigate the prevalence of MS in Mazandaran province after 12 years and the need for possible changes in the global map of the prevalence of MS.

Methods: We included all MS patients living in Mazandaran province in 2018 in this descriptive cross-sectional study. We updated our pre-existing registration questionnaires which included demographic information and medical data of MS patients by interview. We obtained the demographic profile of Mazandaran province from the most recent census in 2016 and the National Civil Registry of the Mazandaran province for calculating prevalence of MS.

Results: The total number of MS patients in Mazandaran was 2418 (25.8% male and 74.2% female) with a female to male ratio of 2.9. Based on the local population of 3,332,556, (50.4% male and 49.6% female), this study showed a prevalence of 72.5 per 100,000 for MS in this region. The prevalence of this disease by gender was 37.1 per 100,000 for men and 108.5 per 100,000 for women. The mean (SD) age of the patients at the time of the study was 38.5 (10.1) years with a minimum of 15 and a maximum of 75 years. The most common type of MS was Relapsing-Remitting MS with 86%.

Conclusions: All recent studies showed significant upward trend in the prevalence of MS around the world. Based on the results of our study and many other studies in Iran, the Atlas of MS prevalence map needs to be update. Iran's status should be changed to the high-prevalence of MS in the new Atlas. Due to the increasing prevalence of MS, we suggest an adjustment in the Global MS Prevalence Scale.
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 Mar 20
Department of Neurology, Faculty of General Medicine, Albert Szent-Györgyi Clinical Centre, University of Szeged, Hungary
Epidemiology of Multiple Sclerosis in Central Europe, Update From Hungary
https://pubmed.ncbi.nlm.nih.gov/32196981/

Abstract

Objectives: Not so long ago, a novel phenotypic classification of multiple sclerosis (MS) and revisions to the McDonald diagnostic criteria were published. Good quality, standardized, and therefore comparable epidemiological data from the Central European region altogether are scarce, and data based on the aforementioned criteria are nonexistent; thus, an update is needed.

Materials and methods: Patients residing in Csongrád county with a definitive diagnosis of MS according to the 2017 McDonald criteria were included and evaluated by the 2014 revised phenotypic classification.

Results: A total of 420 patients were included, of whom 313 were females (female/male ratio 2.925:1). Standardized prevalence was 101.8/100,000, and incidence was 4.44/100,000. Relapsing-remitting disease type was identified in 288 (68.57%) cases, of which 230 patients (79.86%) were treated and of which 202 patients (87.8%) showed no disease activity with their current treatment. Progressive disease type was seen in 132 (31.43%) cases, with 72 patients (54.54%) receiving treatment. More than half of the treated patients (178, 57%) were administered platform therapies, while 134 (43%) received highly active disease modifying therapies.

Conclusion: The prevalence of MS in Hungary similarly to other countries shows a constant increase in the past decades. The majority of our patients received treatment and had a stable disease while being treated. The distribution of disease courses, phenotypes, and treatment status fell in line with data in the literature based on MS registries with a large number of participants. Ours is the first study to give epidemiological data based on the most recent McDonald criteria and phenotypic classification from the Central European region.

-----------------------------
why?
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 Mar 26
From the Department of Neurology (J.S.W., R.M.), Møre og Romsdal Hospital Trust, Molde; Department of Neuromedicine and Olavs University Hospital and Norwegian University of Science and Technology (R.M.), Clinical Trial Unit Central Norway
High incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950-2018.
https://www.ncbi.nlm.nih.gov/pubmed/32217642

Abstract
OBJECTIVE:

To determine prevalence and longitudinal trends in incidence of MS in Møre and Romsdal County, Western Norway, from 1950 to 2018.
METHODS:
Retrospective longitudinal population-based observational study. All patients diagnosed, or living, with MS in Møre and Romsdal were identified as incident or prevalent cases from local, regional, and national sources. We compiled the data in the Norwegian Multiple Sclerosis Registry and Biobank and used the aggregated data set to calculate incidence and prevalence rates using population measures obtained from Statistics Norway.
RESULTS:
On January 1, 2018, the estimated prevalence was 335.8 95% CI, 314.1-358.5 per 100,000 inhabitants, with a female:male ratio of 2.3. From 1950 through 2017, we observed a considerable (p < 0.001) increase in average annual incidence rates from 2.1 (95% CI, 1.3-3.3) to 14.4 (95% CI, 11.9-17.3) per 100,000. From 2005 through 2017, the incidence among women increased from 17.1 (95% CI, 14.0-20.7) to 23.2 (95% CI, 18.7-28.5 per 100,000, whereas the incidence among men declined from 10.3 (95% CI, 7.9-13.2) to 5.9 95% CI, 3.4-8.8 per 100,000.
CONCLUSION:
Møre and Romsdal County in Western Norway has the highest prevalence of MS reported in Norway. The incidence has steadily increased since 1950, and during the latest 15 years, we observed opposing trends in sex-specific incidence rates.
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 Apr 18
Institute of Sport and Exercise Medicine, Division of Orthopaedic Surgery, Department of Surgical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Division of Physiotherapy, Department of Health and Rehabilitation Sciences, Faculty of Health and Medicine, Stellenbosch University, Cape Town, South Africa; IOC Research Centre, South Africa
Multiple Sclerosis in sub-Saharan Africa - A Scoping Review
https://pubmed.ncbi.nlm.nih.gov/32380437/

Abstract

Background: The objective of this review is to provide a synthesis of original studies in patients with MS, originating from sub-Saharan Africa. This review aims to facilitate a better understanding of the MS academic and health landscape in this region.

Methods: A scoping review of original research was conducted (20th of November 2019) in PubMed, SCOPUS, Web of Science and EBSCO host. A narrative synthesis of studies was provided and placed in a historical context.

Results: Thirty-one unique studies from sub-Saharan Africa were identified from 846 unique records. The included studies were predominantly conducted in South Africa (n=24;[77%]) and of case-control (n=11[36%]) or cross-sectional design (n=7[23%]); no randomized clinical trials were identified. Most studies focussed on understanding the epidemiology of MS, the risk of MS in specific ethnic populations, and how this may contribute to identifying the underlying causal pathways.

Conclusion: Albeit scarce, the research conducted in sub-Saharan Africa largely followed international trends. There is a paucity of studies that have been conducted with the primary aim of understanding MS patient care across the continuum, and management of MS in an African context. The latter may become of increasing importance in the light of an increasing prevalence of MS in this region, as well as the increasing noncommunicable disease epidemic.
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 May 11
Neurology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
Epidemiology of Multiple Sclerosis in Santiago De Compostela

Abstract

Objectives: To analyze the frequency and demographic characteristics of multiple sclerosis (MS) in the Council of Santiago de Compostela (SPAIN).

Material and methods: The patients diagnosed with MS according to the McDonald 2010 diagnostic criteria were identified within the population of the District of Santiago de Compostela. Several sources were used (records and databases from Hospital, General Practitioners, Private Clinics, and the MS Patients Association). Demographic and clinical data were obtained from the electronic files.

Results: The incidence of MS between 2010 and 2015 was 8/100 000/year (95% CI: 6-10), and the prevalence on December 31, 2015, was 152/100 000 (95% CI: 127-176). The age-standardized prevalence (using the European Standard Population 2013) was 137 (95% CI: 114-159) and the incidence of 7 (95% CI: 2-12). The female:male ratio was 1.84, the mean age at the first symptom was 32.23 years, the diagnosis was delayed 3.12 years, and the mean EDSS was 2.82. 71.17% had relapsing-remitting MS, 16.55% secondary progressive MS, 7.59% primary progressive MS, and 0.69% progressive relapsing MS. A disease-modifying treatment was established in 62.76% of patients in a mean of 1.96 years after the diagnosis.

Conclusions: The northwest of Spain is a high-risk area for MS, with frequencies similar to other Atlantic regions and higher than the rest of the country.
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 May 18
Department of Neurology, Neurosurgery and Medical Genetic, Prirogov Russian National Research Medical University, Moscow, Russia
Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies
https://pubmed.ncbi.nlm.nih.gov/32443404/

Abstract

In the Russian Federation, multiple sclerosis prevalence rates vary from 10 to 80 cases per 100,000, depending on region and the nationality of the population. The main characteristics of multiple sclerosis epidemiology in the XX century in this big territory are: (1) steady increase in multiple sclerosis prevalence and incidence rates, maybe because of better diagnosis and treatment, but also changes in environmental/epigenetic risk profile and/or lifestyle factors; (2) increase of the female to male ratio, increase in multiple sclerosis incidence mainly in females; (3) appearance and increasing frequency of multiple sclerosis in ethnic groups, previously free of multiple sclerosis (Northern Tribes, Yakuts and others). The latest data show that in European Russia, the multiple sclerosis prevalence varies from 30 to 80 cases, in Siberia-from 20 to 70 cases, with steady increases, especially in women.
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 Jun 4
Division of Clinical Neurosciences, Turku University Hospital, University of Turku, Finland
Changes in Multiple Sclerosis Epidemiology in Finland Over Five Decades
https://pubmed.ncbi.nlm.nih.gov/32500607/

Abstract

Finland is a high-risk region for multiple sclerosis (MS) with several epidemiological studies on the subject published since 1964, but these have not been comprehensively scrutinized. The objective of this study was to review previous studies of Finnish MS epidemiology, introduce new data on MS prevalence in western parts of Finland and do further analyses on data from previous studies. We performed a systematic search on articles regarding MS epidemiology in Finland in PubMed database, and all relevant articles were included in this review. MS prevalences in the western hospital districts of Vaasa, South Ostrobothnia and Pirkanmaa were calculated in 1980-2007 by using previously unpublished data obtained from a retrospective search from hospital administrative registries. To enhance comparability of the epidemiological figures, we calculated age-standardized prevalence of MS from the new data from western hospital districts and previous data from North Ostrobothnia, Southwest Finland and North Karelia. Marked regional differences in MS epidemiology were confirmed with concentration of the disease in the western and south-western parts of the country. The highest regional age-standardized MS prevalence of 288/100 000 was reported in South Ostrobothnia in 2007. A clear and stable increase in MS prevalence was observed through the decades, but the only marked increase in incidence happened in 1990s. Methodological differences hampered direct comparisons of different studies, highlighting the importance of common principles of reporting and standardizing the epidemiological figures. More comprehensive studies on MS epidemiology are still warranted to yield important information concerning the aetiology of the disease.


--------------------------------------------------------------------
Why?
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 Jun 2
Serviço de Neurologia do Hospital do Divino Espírito Santo de Ponta Delgada, EPE, Portugal
Incidence, Prevalence and Characteristics of MS in São Miguel, an Island in the Atlantic
https://pubmed.ncbi.nlm.nih.gov/32562908/

Abstract

Background: Multiple sclerosis (MS) is a chronic inflammatory-demyelinating disease of the central nervous system (CNS). With approximately 2.3 million people estimated to live with MS globally, incidence and prevalence of the disease vary significantly across regions. Generically, the global distribution of MS varies with geographic latitude. However, MS epidemiological data in Southern Europe and Mediterranean countries revealed areas of unexpectedly high prevalence and incidence of MS, thereby demonstrating that clear exceptions to the variation of MS with latitude exist. Epidemiological evidence on MS in Portugal is limited to studies concerning specific regions of the country and therefore not representative of the entire country. More studies form different regions of the country are needed in order to effectively establish MS prevalence and incidence in Portugal. The aim of this study is to determine MS incidence and prevalence, as well as gather information on other clinical data in São Miguel, the biggest island of the Azores, a Portuguese archipelago situated in the North Atlantic...
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2020 Dec
Multiple Sclerosis International Federation, London, UK
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
https://pubmed.ncbi.nlm.nih.gov/33174475/

Abstract

Background: High-quality epidemiologic data worldwide are needed to improve our understanding of disease risk, support health policy to meet the diverse needs of people with multiple sclerosis (MS) and support advocacy efforts.

Objectives: The Atlas of MS is an open-source global compendium of data regarding the epidemiology of MS and the availability of resources for people with MS reported at country, regional and global levels.

Methods: Country representatives reported epidemiologic data and their sources via survey between September 2019 and March 2020, covering prevalence and incidence in males, females and children, and age and MS type at diagnosis. Regional analyses and comparisons with 2013 data were conducted.

Results: A total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population). MS prevalence has increased in every world region since 2013 but gaps in prevalence estimates persist. The pooled incidence rate across 75 reporting countries is 2.1 per 100,000 persons/year, and the mean age of diagnosis is 32 years. Females are twice as likely to live with MS as males.

Conclusions: The global prevalence of MS has risen since 2013, but good surveillance data is not universal. Action is needed by multiple stakeholders to close knowledge gaps.



----------------------------
why?
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2021 Jan 31
Department of Neurology, Siun sote, North Karelia Central Hospital, Joensuu, Finland; Clinical Neurosciences, University of Turku, Turku, Finland
Nordic clues for uncovering the aetiology of Multiple Sclerosis
https://pubmed.ncbi.nlm.nih.gov/33561666/

Abstract

Our understanding of the etiology of multiple sclerosis (MS) is inadequate to effectively combat the increasing incidence and prevalence of the disease. Environmental factors are of crucial importance but more information about them is needed. Recent results of incidence trends over several decades in Denmark, Norway and Finland provide suggestions for further studies on the subject. Since incidence trends show marked differences by region and sex taking these factors into account when investigating birth cohort exposures could provide important new insights. Exposures during the first 15 years of life should be prioritized. International and multidisciplinary co-operation is needed.
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2021 Apr 20
Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon
Epidemiology of multiple sclerosis in Lebanon: A rising prevalence in the middle east
https://pubmed.ncbi.nlm.nih.gov/33934011/

Abstract

Background: The epidemiology of multiple sclerosis (MS) has been studied in many countries of the Middle East but the prevalence and incidence of MS in Lebanon is still unknown.

Objectives: To determine the incidence and prevalence of MS in Lebanon.

Methods: Lebanese patients diagnosed with MS between January 2018 and December 2018 were identified using the database of governmental third-party payers. The crude, age- and sex-specific 2018 prevalence and incidence among Lebanese patients were calculated.

Results: 2248 MS patients were identified of whom 67.1% were women (female: male ratio 2:1) with a mean age of 41.8 ± 12.96 years. The 2018 prevalence of MS was 62.91 cases per 100,000 persons (95% CI: 60.41 - 65.41). The overall incidence of MS in Lebanon was 8.36 cases per 100,000 (95% CI: 7.45 - 9.27) with a mean age at onset of 34.5 ± 12.5 years.

Conclusion: This is the first study to assess prevalence and incidence of MS in Lebanon, confirming that Lebanon is a moderate to high-risk area for MS. Those high rates are commensurate with recently published studies from the Middle East, pointing to a significant rise in incidence and prevalence of this disease in our region.


----------------------------------------
why?
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2021 Apr 24
Neurology Department, Hospital Clínico Universitario, Santiago de Compostela, (A Coruña), Spain
Temporal trends in the incidence and prevalence of Multiple Sclerosis in the Northwest of Spain
https://pubmed.ncbi.nlm.nih.gov/33964571/

..Conclusion:
The prevalence of MS doubled in 12 years whilst the difference in incidence was lower and not significant. The disproportion in the growth of both parameters, as well as the higher mean age in the last study, suggest a longer survival of patients with MS.
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2021 Jul 14
India State-Level Disease Burden Initiative Neurological Disorders, Funding: Bill & Melinda Gates Foundation; and Indian Council of Medical Research, Department of Health Research
The burden of neurological disorders across the states of India: the Global Burden of Disease Study 1990-2019
https://pubmed.ncbi.nlm.nih.gov/34273302/

..Interpretation: The increasing contribution of non-communicable and injury-related neurological disorders to the overall disease burden in India, and the substantial state-level variation in the burden of many neurological disorders highlight the need for state-specific health system responses to address the gaps in neurology services related to awareness, early identification, treatment, and rehabilitation.

-----------------------------
Does anyone know what was the trend the MS of the World in 2020 ?? Thank you
https://www.eboro.cz
User avatar
Petr75
Family Elder
Posts: 1615
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic
Contact:

Re: Prevalence

Post by Petr75 »

2021 Aug 15
Instituto de Neurociencias de Rosario, Rosario, Argentina
Prevalence of Multiple Sclerosis in Rosario, Argentina
https://pubmed.ncbi.nlm.nih.gov/34418739/

Abstract

Background: The prevalence and incidence of Multiple Sclerosis have been increasing worldwide over the last decades. Most of the publications during the last years outstand the prevalence in Europe, North America and Latin America. In Argentina, data published on this topic is scarce and most of the studies took place in Buenos Aires. In a recent publication, we reported an MS prevalence rate of 30.3/100,000 in the overall extension of Santa Fe, Argentina...
https://www.eboro.cz
Post Reply

Return to “General Discussion”